De Laere Pharma SRL
De Laere Pharma reported total assets of 94,125 € at the end of the 2025 financial year (annual accounts filed with the NBB on 26 Jun 2026).
The score of De Laere Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +12 % Total assets +89 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
De Laere Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 26 Jun 2026
- Year ended 31 Dec 2024filed on 17 Jun 2025
- Year ended 31 Dec 2023filed on 10 Jun 2024
- Year ended 31 Dec 2022filed on 02 Jun 2023
- Year ended 31 Dec 2021filed on 29 Jun 2022
De Laere Pharma's financial analysis
- Solvency42.9%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of De Laere Pharma
De Laere Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0763.546.683
- VAT number
- BE0763546683
- Peppol
- Registered · 0208:0763546683 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 12 Feb 2021
- Registered office
- 8670 Koksijde
- Latest accounts
- 2025 · filed on 26 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
De Laere Pharma (SRL) has been based in Koksijde since 2021, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 14,118 € and equity of 40,411 €; its revenue is not published. Its solvency stands at 42.9%, below the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to De Laere Pharma
Companies in the same business, of comparable size and area, outside its group.
- Hubert Services Management Retail sale of pharmaceutical products Estinnes · balance sheet 65,144 €
- Mieke de Geeter Retail sale of pharmaceutical products Kortrijk · balance sheet 58,191 €
- Farma & Fit Retail sale of pharmaceutical products Rotselaar · balance sheet 71,427 €
- Liesap Retail sale of pharmaceutical products Wichelen · balance sheet 72,120 €
- Yascare Retail sale of pharmaceutical products Uccle · balance sheet 34,424 €
- Panax Retail sale of pharmaceutical products Wemmel · balance sheet 99,320 €
- Kato van Vooren Retail sale of pharmaceutical products Dendermonde · balance sheet 88,886 €
- Van Aelst Leonie Retail sale of pharmaceutical products Beernem · balance sheet 86,688 €
Frequently asked questions about De Laere Pharma
What is the revenue of De Laere Pharma?
De Laere Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of De Laere Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0763546683 for De Laere Pharma, if the company is VAT-registered. Its company number (CBE) is 0763.546.683.
Where is the registered office of De Laere Pharma?
According to the CBE register, the registered office of De Laere Pharma is in 8670 Koksijde.
What is the equity of De Laere Pharma?
At the close of the 2025 financial year, the equity of De Laere Pharma amounts to 40,411 €, a solvency of 42.9% of total assets.
Who manages De Laere Pharma?
The register lists 2 active mandates at De Laere Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of De Laere Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →